*4.3.7 Compliance with drugs and treatment*

According to the recommendations of the ESC/HFA guidelines related to heart failure, regular follow-up and monitoring of biomedical parameters is useful in providing safety and the optimal dose of drugs and the determination of the development of complications or disease progression [37].

Pharmacological treatment of heart failure consists of several different drugs that have different dose strategies, especially in heart failure patients with reduced ejection fraction [HFrEF]. When the drugs for frequently seen comorbidities such as atrial fibrillation, hypertension, and diabetes are taken into consideration, the result is a labyrinthine, continuously changing drug regimen that requires time, presence of mind, and dedication for successful compliance [38].
